Grifols, S.A. (BME:GRF)
Spain · Delayed Price · Currency is EUR | Market Cap | 5.61B -1.1% |
| Revenue (ttm) | 7.52B +4.3% |
| Net Income | 402.00M +156.1% |
| EPS | 0.59 +156.5% |
| Shares Out | 680.58M |
| PE Ratio | 15.34 |
| Forward PE | 9.83 |
| Dividend | 0.30 (3.26%) |
| Ex-Dividend Date | Aug 11, 2025 |
| Volume | 2,463,741 |
| Average Volume | 2,489,885 |
| Open | 9.19 |
| Previous Close | 9.20 |
| Day's Range | 8.95 - 9.25 |
| 52-Week Range | 7.32 - 13.70 |
| Beta | 1.20 |
| RSI | 40.33 |
| Earnings Date | May 5, 2026 |
About Grifols
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as wel... [Read more]
Financial Performance
In 2025, Grifols's revenue was 7.52 billion, an increase of 4.33% compared to the previous year's 7.21 billion. Earnings were 402.00 million, an increase of 156.05%.
Financial StatementsNews
Ban Grifols and return plasma collection to Canadian Blood Services and Héma-Québec, say health care advocates
OTTAWA, March 30, 2026 (GLOBE NEWSWIRE) -- Proponents of public universal health care across Canada are calling for the closure of Grifols facilities in the wake of two deaths in Winnipeg of people wh...
Grifols approves IPO of its US biopharma business
Healthcare company Grifols said on Tuesday it has approved a U.S. initial public offering of its U.S. biopharma business.
Grifols Shares Results From its Chronos Platform Identifying Early Molecular Changes Associated with Parkinson's Disease
BARCELONA, Spain, March 17, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today shared proof-of-conc...
Health Coalition demands disclosures & end to Grifols' for-profit blood plasma contract following reports of deaths, harm, non-compliance
TORONTO, March 13, 2026 (GLOBE NEWSWIRE) -- The Ontario and Manitoba Health Coalitions held a press conference this morning to respond to a report from CBC about two patients who died in Winnipeg af...
Media Advisory: Press Conference Regarding Tragic Deaths After Plasma Harvesting at Grifols' Sites
WINNIPEG, Manitoba and TORONTO, March 12, 2026 (GLOBE NEWSWIRE) -- What: Spokespeople from the Manitoba Health Coalition and Ontario Health Coalition will respond to the sad news of two deaths of paid...
Grifols doubles net profit in 2025, driven by revenues
Spanish drugmaker Grifols reported on Thursday a net profit of 402 million euros ($473.96 million) for 2025, more than double what it recorded the previous year, driven by revenues of 7.5 billion euro...
Spanish court summons Gotham City founder in Grifols share price probe
Spain's High Court on Thursday summoned the founder of U.S.-based short seller Gotham City Research, Daniel Yu, to testify over allegations his company disseminated misleading information about pharma...
XL-protein grants worldwide license to Grifols to develop a biopharmaceutical using PASylation® technology
Freising, Germany, June 10, 2025 — XL-protein GmbH, a pioneer in the area of biopolymers for pharmacokinetic optimization, announced today that it has entered into a worldwide License, Development and...
Mason Capital Management to Support Grifols Recommended Director Slate at Upcoming Ordinary General Meeting
NEW YORK--(BUSINESS WIRE)--Mason Capital Management LLC (“Mason”), a registered investment advisor to funds and accounts holding approximately 3% of Grifols S.A. (“Grifols” or the “Company”) (BME: GRF...
US court finds enough evidence to proceed with Grifols lawsuit against Gotham City
A New York court found enough evidence to continue with the defamation lawsuit filed by Spanish pharmaceutical company Grifols against short seller Gotham City Research, Grifols said in a statement on...
Grifols says on course to meet 2025 outlook as net profit triples
Grifols's net profit almost tripled from a year earlier, which the Spanish drugmaker said reinforced its confidence in meeting its full-year guidance.
IBL International collaborates with Grifols on advanced biomarker panels
MÄNNEDORF, Switzerland--(BUSINESS WIRE)--IBL International GmbH, a Tecan company, which develops, manufactures and offers specialty diagnostics, today announced a strategic partnership with Grifols, a...
Brookfield resumes Grifols takeover talks, El Confidencial reports
Canadian investment fund Brookfield has resumed talks on a potential takeover of Spanish pharmaceuticals company Grifols four months after a previous attempt fell through, news website El Confidencial...
Grifols expects to boost revenue and free cash flow, shares soar
Spanish drugmaker Grifols said on Thursday it expects its revenue, core earnings and free cash flow to grow significantly in the coming years as it aims to leave behind a tumultuous 2024 when it lost ...
Grifols' sales rise over 10% in 2024, above target
Spanish drugmaker Grifols reported on Wednesday a net profit of 157 million euros ($165.02 million) for 2024 on revenues of 7.21 billion euros, up 10.2% from a year earlier and above its target for 7%...
Blood Plasma Derivatives Market Insights and Forecast 2025-2030 - Grifols, SK Plasma, and Fusion Health Care Lead the Competition
Rising Incidence of Hemophilia, Immunological Disorders, and the Growing Number of Surgical Procedures Worldwide is Driving Growth, at a CAGR of ~9% Rising Incidence of Hemophilia, Immunological Disor...
Grifols Pioneers High-Tech Analysis of Plasma Bank to Detect Early Signs of Parkinson's Disease
BARCELONA, Spain, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Grifols (MCE: GRF, MCE: GRF.P, and NASDAQ: GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced it h...
Mason Capital complains about Grifols' transparency to Spanish regulator
U.S.-based investment fund Mason Capital said on Monday it had sent a letter to Spain's stock market regulator CNMV demanding more transparency from the embattled pharmaceutical company Grifols.
Mason Capital Management Sends Letter to Spanish National Securities Market Commission Regarding Lack of Transparency by Grifols
NEW YORK--(BUSINESS WIRE)--Mason Capital Management LLC (“Mason”), a registered investment advisor to funds and accounts holding approximately 2.5% of Grifols S.A. (“Grifols” or the “Company”) (BME: G...
Flat Footed Calls for Prompt Governance Overhaul at Grifols
BARCELONA, Spain--(BUSINESS WIRE)--Flat Footed LLC is the investment manager for FF Hybrid LP, Flat Footed Series LLC - Fund 3, and GP Recovery Fund LLC (collectively, with Flat Footed LLC, “Flat Foot...
Spain's market regulator sees signs of manipulation in Grifols-Gotham dispute
The outgoing head of Spain's stock market regulator CNMV, Rodrigo Buenaventura, told reporters on Thursday that there were signs of possible market manipulation in the dispute between short seller Got...
Mason Capital Management Requests Immediate Disclosure of Important Information Regarding Conflicted Grifols Director Tomas Daga
NEW YORK--(BUSINESS WIRE)--Mason Capital Management LLC (“Mason”), a registered investment advisor to funds and accounts holding approximately 2.1% of Grifols S.A. (“Grifols” or the “Company”) (BME: G...
Statement From Araoz y Rueda on Behalf of Certain Institutional Investors in Grifols
MADRID--(BUSINESS WIRE)--Law firm Araoz y Rueda has been independently engaged by several international and Spanish institutions (the “Clients”) holding in aggregate 5.65% of A shares and 3.88% of B s...
Why Is Spanish Healthcare Grifols Stock Trading Lower On Friday?
On Wednesday, Grifols SA GRFS said it ended discussions with Brookfield Capital Partners (UK) Limited about a potential acquisition.
Grifols shares tumble after report on Brookfield abandoning takeover plan
Shares in Grifols were falling on Wednesday morning after Bloomberg reported Canadian fund Brookfield is considering dropping its plan to take over the Spanish pharmaceutical firm.